Posted by Michael Wonder on 22 Nov 2023
MSAC publishes agenda for April MSAC meeting
22 November 2023 - The MSAC Secretariat has published a list of applications scheduled to be considered by the MSAC on 4-5 April 2024.
The agenda currently has 14 items. Applications of note include:
1708 – Hepatitis delta virus RNA PCR testing to determine eligibility for PBS subsidised bulevirtide acetate (Hepcludex) for treatment of patients with hepatitis D virus infection
1722.1 – Axicabtagene ciloleucel (Yescarta) for the treatment of patients with relapsed or refractory large B-cell lymphoma
1765 – Amendment of MBS items 73303 and 73304 (BRCA1/2 mutation testing in patients with metastatic castration-resistant prostate cancer) to include talazoparib tosylate (Talzenna)
